Key result
Phospholipase A2 inhibitors may prevent ventricular arrhythmias by blocking iPLA2-mediated inflammatory metabolite release.
Why the study?
Inflammatory and immune mechanisms play a critical role in atherogenesis and thrombosis, but the therapeutic potential of phospholipase A2 inhibitors in cardiovascular disease remains to be clarified.
Inhibition of iPLA2 may represent a therapeutic target for preventing inflammation-driven atherogenesis and ischemia-induced ventricular arrhythmias.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mary C. White (2007) conducted a review in Cardiovascular Disease. Phospholipase A2 Inhibitors was evaluated. Phospholipase A2 inhibitors may offer therapeutic potential in cardiovascular disease by preventing iPLA2-mediated release of inflammatory metabolites that trigger ventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: